Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: A meta-analysis

Gene

Volumn 507, Issue 1, 2012, Pages 27-35

  Shi, Ke Qing ^a,b   Liu, Wen Yue ^a,b   Lin, Xian Feng ^a,b   Fan, Yu Chen ^c   Chen, Yong Ping ^a,b   Zheng, Ming Hua ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Hepatitis C virus; Interleukin 28B; Single nucleotide polymorphisms; Sustained virological response; Systematic review

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN;

AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; COCHRANE LIBRARY; EMBASE; ETHNICITY; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HEPATITIS C; HETEROZYGOSITY; HISPANIC; HUMAN; LIVER FIBROSIS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84864966195     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.07.026     Document Type: Article

References (49)

1. Abe H., et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 2011, 54:1094-1101.
2. Berg T., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003, 37:600-609.
3. Bitetto D., et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011, 53:1118-1126.
4. Bochud P.Y., et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J. Hepatol. 2011, 10.1016/j.jhep.2011.01.050.
5. Chen J.Y., et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011, 12:300-309.
6. Clark P.J., Thompson A.J., McHutchison J.G. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am. J. Gastroenterol. 2011, 106:38-45.
7. Costa J.M., et al. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin. Res. Hepatol. Gastroenterol. 2011, 35:204-213.
8. Darling J.M., et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011, 53:14-22.
9. de Boer A.G., Taskila T., Ojajarvi A., van Dijk F.J., Verbeek J.H. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009, 301:753-762.
10. de Rueda P.M., et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am. J. Gastroenterol. 2011, 10.1038/ajg.2011.82.
11. Di Martino V., et al. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology 2011, 10.1002/hep.24480.
12. Dill M.T., et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140:1021-1031.
13. Fattovich G., et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment. Pharmacol. Ther. 2011, 33:1162-1172.
14. Galmozzi E., et al. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J. Viral Hepat. 2010, 10.1111/j.1365-2893.2010.01349.x.
15. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
16. Grebely J., et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216-1224.
17. Hayes C.N., et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011, 60:261-267.
18. Honda M., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509.
19. Hsu C.S., et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3719-3724.
20. Janssens A.C., Ioannidis J.P., van Duijn C.M., Little J., Khoury M.J. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. PLoS Med. 2011, 8:e1000420.
21. Kawaoka T., et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 2011, 54:408-414.
22. Kurosaki M., et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol. 2011, 54:439-448.
23. Lagging M., et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011, 6:e17232.
24. Li J.H., et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010, 51:1904-1911.
25. Liao X.W., et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir. Ther. 2011, 16:141-147.
26. Lin C.Y., et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6:e18322.
27. Lindh M., Lagging M., Norkrans G., Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010, 139:1794-1796.
28. Mangia A., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827. e1.
29. Mangia A., et al. Limited utility of IL28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 10.1002/hep.24458.
30. McCarthy J.J., et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
31. McHutchison J.G., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361:580-593.
32. Moghaddam A., et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011, 53:746-754.
33. Montes-Cano M.A., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
34. Patel K., et al. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology 2011, 53:1809-1818.
35. Rauch A., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. 1345 e1-7.
36. Reiberger T., et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 2011, 9:602-608. e1.
37. Romero-Gomez M., Eslam M., Ruiz A., Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 2011, 31:443-460.
38. Sakamoto N., et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J. Med. Virol. 2011, 83:871-878.
39. Sarrazin C., et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011, 54:415-421.
40. Scherzer T.M., et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J. Hepatol. 2011, 54:866-871.
41. Shirakawa H., et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-1760.
42. Sinn D.H., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J. Gastroenterol. Hepatol. 2011, 10.1111/j.1440-1746.2011.06744.x.
43. Stattermayer A.F., et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011, 9:344-350. e2.
44. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
45. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
46. Thomas D.L., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
47. Thompson A.J., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. e18.
48. Yu M.L., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.
49. Zheng M.H., Shi K.Q., Fan Y.C., Chen Y.P. Meta-analysis using individual participant data is the gold standard for diagnostic studies. Hepatology 2011, 53:1062. author reply 1062-3.